Clinical Trial Update: EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction [Phase 3]

View source ↗

Summary

Phase 3 trial update for empagliflozin assessing its ability to prevent worsening of left ventricular volumes and systolic function after myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: NHS Greater Glasgow and Clyde | Conditions: Myocardial Infarction | Phase 3 | Status: ACTIVE_NOT_RECRUITING